Detail akcie Codexis online

Business Summary: Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Codexis Inc revenues decreased 15% to $59.3M. Net loss decreased 14% to $65.3M. Revenues reflect China segment decrease of 52% to $9.8M, APAC segment decrease of 67% to $4.4M, Switzerland segment decrease of 69% to $3.4M. Lower net loss reflects Technology Platform segment loss decrease of 14% to $58.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.12 to -$0.89.